KAI Pharma out-licenses KAI-4169 to Ono for Japan

19 September 2011

Privately-held USA-based drug discovery firm KAI Pharmaceuticals has signed an agreement with Ono Pharmaceutical (TYO: 4528) for the development and commercialization in Japan of KAI-4169, its lead product candidate.

KAI-4169 is a novel therapeutic agent in Phase II clinical testing in the USA as an intravenous formulation for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease-mineral and bone disorder (CKD-MBD). Under the terms of the agreement, Ono receives exclusive rights to all indications for injectable formulations of KAI-4169 in Japan, while KAI retains commercialization rights in all other regions of the world.

$13 million upfront plus milestones

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK